Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

 
• By Mandy Jackson
  
Human kidney cross section on scientific background showing adrenal gland as well. 3d illustration
Acquiring Peloton will expand Merck's kidney cancer portfolio • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business